Journal of Clinical Oncology
Articles in this Issue
Neoadjuvant radio-chemoimmunotherapy versus neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer: A pooled analysis of prospective studies.
e20063 Background: Neoadjuvant chemoimmunotherapy (CI) is the standard of care for locally advanced, resectable non-small cell lung cancer (NSCLC). Due to...
Incidence and survival rates of patients with primary malignant cardiac tumors: A SEER based study.
e24007 Background: Primary cardiac tumors (PCTs) are rare growths, comprising less than 1% of all cardiac tumors, with cardiac metastases occurring 30-tim...
Public health policy and cancer prevention: Impact of HPV vaccine laws on oropharyngeal cancer.
e23046 Background: Oropharyngeal cancer is a significant global health challenge and the sixth most common cancer worldwide. Human Papillomavirus (HPV) va...
POD1UM-303/INTERAACT2 subgroup analyses and impact of delayed retifanlimab treatment on outcomes in patients with squamous cell carcinoma of the anal canal (SCAC).
3525 Background: SCAC is a rare cancer with high unmet medical need and no FDA-approved treatment options. POD1UM-303 is the only phase 3 study of systemi...
Deep learning–based prediction of neoadjuvant therapy response in HER2-positive breast cancer through histopathology images of core biopsies: A multicenter study.
e12597 Background: Early-stage HER2-positive breast cancer patients who achieve pathological complete response (pCR) after neoadjuvant therapy generally e...
The role of platinum-free interval in advanced endometrial cancer treatment: A real-world study of 843 patients.
5609 Background: Time between completion of last platinum-based chemotherapy (PBC) and recurrence is predictive of outcomes in recurrent ovarian cancer; h...
Reassessing colorectal cancer recurrence in solid organ transplant recipients: Implications for revised management guidelines.
3620 Background: Patients with solid organ transplants (SOT) are at an increased risk of developing secondary malignancies, including colorectal cancer (C...
An evaluation of machine learning techniques for the diagnosis of gastric cancer: A meta analysis.
e16078 Background: Gastric cancer is a leading cause of cancer mortality worldwide, with early detection crucial for better survival. Recent advancements...
Comparative assessment of colitis-related adverse events in multiple myeloma patients treated with teclistamab, ciltacabtagene, and idecabtagene: Incidence, outcomes, and risk assessment.
e19510 Background: Colitis, an inflammation of the colon, is a significant adverse event (AE) increasingly seen in patients with multiple myeloma treated...
Real-world (RW) outcomes of patients (pts) with lower-risk myelodysplastic syndrome (LR-MDS) receiving first-line (1L) luspatercept (LUSPA) or 1L erythropoiesis-stimulating agents (ESA) in the US.
6570 Background: LR-MDS pts receiving ESAs for anemia often experience treatment (tx) resistance or relapse. Evidence from the COMMANDS trial led to LUSPA...
Peptide receptor radionuclide therapy (Lu-177 PRRT) in neuroendocrine tumors (NET): Single institution experience over 15 years.
e16343 Background: Peptide receptor radionuclide therapy (PRRT) is one of the standard treatments for unresectable or metastatic neuroendocrine tumors (NE...
A non-invasive metabolomic biomarker for detecting cervical intraepithelial neoplasia and cervical cancer.
5532 Background: Cervical intraepithelial neoplasia (CIN) is a precancerous lesion that can progress to cervical cancer, a leading malignancy affecting wo...
Effectiveness, safety for bone marrow protection of trilaciclib for patients with locally advanced carcinoma: A real-word evidence analysis.
e15109 Background: Trilaciclib as the selective and reversible CDK4/6 inhibitor was approved for use in patients with extensive stage small cell lung canc...
Label-free detection of visceral pleural invasion in lung adenocarcinoma using multiphoton microscopy.
e20073 Background: Visceral pleural invasion (VPI) constitutes a significant pathological factor in non-small cell lung cancer (NSCLC). The rapid and accu...
Systematic review of 2L+ ADC strategies in triple-negative breast cancer (TNBC).
e15009 Background: TNBC is highly aggressive with limited treatment options in the 2L+ setting, underscoring critical unmet clinical needs. Recent strateg...
ALISertib in combination with endocrine therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2–) recurrent or metastatic breast cancer: The phase 2 ALISCA-Breast1 study.
TPS1125 Background: Despite the many available treatments for patients (pts) with HR+, HER2– recurrent/metastatic breast c...
FICO scores and borrowing patterns among hematology-oncologists compared to other medicine subspecialties: A cross-sectional analysis.
e23148 Background: The average cost for tuition, fees, and living expenses exceeds $275,000 at 50% of U.S. medical schools. In addition, Hematologist-Onco...
Impact of urinary tract infections on in-hospital outcomes among prostate cancer patients: An NIS-based analysis.
e17013 Background: Prostate cancer, the second most diagnosed cancer in men worldwide, predominantly affects older individuals who may experience obstruct...
Stereotactic body radiation therapy (SBRT) for prostate-specific membrane antigen positron emission tomography (PSMA-PET)–detected oligometastatic prostate cancer: A real world analysis of patients treated in a reference center.
e17156 Background: Stereotactic body radiation therapy (SBRT) is a useful therapy for patients with oligometastatic prostate cancer (OPC). SBRT benefits p...
Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1.
7504 Background: Elranatamab (ELRA), a BCMA-CD3 bispecific antibody, induced deep and durable responses with a manageable safety profile in patients (pts)...
First-in-human phase I/II study of BYS10 in patients (pts) with locally advanced or metastatic RET-altered solid tumors: Preliminary dose escalation results.
8601 Background: RET alterations occur in non-small cell lung cancer (NSCLC, 2%), thyroid cancer (TC, 10%–20%) and a range of tumor types (<1%). RET in...
Safety and antitumor activity of <sup>177</sup> Lu-catelase: A preliminary clinical study in soft tissue sarcoma.
11563 Background: Localized radiotherapy with radioisotope injections holds promise but is limited by poor tumor retention and hypoxia. To overcome these...
Prognostic value of postoperative circulating tumor DNA and tumor markers in resected pancreatic adenocarcinoma (PAAD): An interim analysis of a prospective observational study.
4192 Background: Despite the benefits of postoperative adjuvant chemotherapy, recurrence rates of PAAD remain as high as 60% within the first year, unders...
Age-related germline landscape of endometrial cancer: Focus on early-onset cases.
10575 Background: Endometrial cancer (EC) has traditionally been associated with older age; however, recent trends indicate more cases in younger women. T...
Adherence of published randomized phase 3 cancer trials to principles proposed by common-sense oncology.
11019 Background: Randomized clinical trials (RCTs) remain the gold standard for evaluating the efficacy and safety of novel cancer therapies. Some RCTs a...